-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $229

Benzinga·04/22/2026 13:27:52
Listen to the news
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.